U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  FORM 12B-25

                          NOTIFICATION OF LATE FILING

                        Commission File Number  0-27675

(Check One):   [X] Form 10-K [ ] Form 20-F  [ ] Form 11-K  [ ] Form 10-Q
               [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR

               For Period Ended:    March 31, 2008
                                    --------------

               [ ] Transition Report on Form 10-K
               [ ] Transition Report on Form 20-F
               [ ] Transition Report on Form 11-K
               [ ] Transition Report on Form 10-Q
               [ ] Transition Report on Form N-SAR
               FOR THE TRANSITION PERIOD ENDED:_______________

  Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.
    NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS
                   VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Stem Cell Therapy International, Inc
------------------------------------
Full Name of Registrant


------------------------------------
Former Name if Applicable

2203 N. Lois Avenue, 9th Floor
------------------------------
Address of Principal Executive Offices (Street and Number)

Tampa, FL 33607
---------------
City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25 (b), the following
should be completed. (Check appropriate box)


[X]     (a) The reasons described in reasonable detail in Part III of this form
            could not be eliminated without unreasonable effort or expense;

[X]     (b) The subject annual report, semi-annual report, transition report on
            Form 10-K, 10-KSB, 20-F, 11-K or Form N-SAR, or portion thereof
            will be filed on or before the 15th calendar day following the
            prescribed due date; or the subject quarterly report or
            transition report on Form 10-Q, 10-QSB, or portion thereof will
            be filed on or before the fifth calendar day following the
            prescribed due date; and

[ ]     (c) The accountant's statement or other exhibit required by Rule
            12b-25(c) has been attached if applicable.

                                 Page 1 of 2

                                    PART III
                                   NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 10-KSB, 11-K. 20-F,
10-Q, 10-QSB, N-SAR, or the transition report or portion thereof could not be
filed within the prescribed time period. (Attach extra sheets if needed.)

The registrant has experienced delays in completing its financial statements for
the  year  ended  March  31,  2008,  as the registrant's auditors were unable to
timely  complete  their  audit. As a result, the registrant is delayed in filing
its  Form  10-K  for  the  year  ended  March  31,  2008.

                                    PART IV
                               OTHER INFORMATION

(1)  Name and telephone number of person to contact in regard to this
     notification

     M. Richard Cutler                706                    737-6600
     -----------------                ---                    --------
          (Name)                   (Area Code)          (Telephone Number)

(2)  Have all other periodic reports required under Section 13 or 15(d) of the
     Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
     of 1940 during the preceding 12 months or for such shorter period that the
     registrant was required to file such report(s) been filed? If the answer is
     no, identify report(s).                                      [X] Yes [ ] No

(3)  Is it anticipated that any significant change in results of operations from
     the corresponding period for the last fiscal year will be reflected by the
     earnings statements to be included in the subject report or portion
     thereof?                                                     [ ] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

                     STEM CELL THERAPY INTERNATIONAL, INC.
                     -------------------------------------
                  (Name of Registrant as specified in charter)

Has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.



Date: June 30, 2008             By: /s/ Andrew J. Norstrud
      -------------                 ----------------------
                                    Andrew J. Norstrud, Chief Financial Officer




















                                 Page 2 of 2